The Lancet Oncology Q1 Unclaimed
The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 305. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer, . It has an SJR impact factor of 15,65 and it has a best quartile of Q1. It is published in English.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2395 €
Gold OA-
Green OA0 €
Non OAMetrics
15,65
SJR Impact factor305
H Index618
Total Docs (Last Year)1958
Total Docs (3 years)8994
Total Refs18292
Total Cites (3 years)540
Citable Docs (3 years)31
Cites/Doc (2 years)14,55
Ref/DocAims and Scope
Other journals with similar parameters
Nature Reviews Clinical Oncology Q1
CA - A Cancer Journal for Clinicians Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of the National Cancer Institute Q1
Best articles
A new approach to managing prostate cancer is essential
View moreA paperchase
View moreAdjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28
View moreAlan Coates -CEO of the Australian Cancer Society
View moreAllan van Oosterom, President of the EORTC
View moreAlternative cancer cures
View moreAlternative medicine and cancer patients in less developed countries
View moreAmgen's point of view on epoetins
View moreAn extra defence against skin cancer?
View moreAssociation of the British Pharmaceutical Industry says...
View moreAustralia approves thalidomide
View moreAustralian cancer survival figures greatly improved
View moreAustralian scientists design novel antiangiogenic weapon
View moreBreast cancer in women after treatment for Hodgkin's disease
View moreBreast reconstruction cannot exorcise phantom pain
View moreBring back the acetyls - a novel anticancer movement
View moreCanadian researchers uncover vital new clues in cancer
View moreCancer and ethnic minorities
View moreCancer Institute at Chennai: a model for resource-poor countries
View moreCancer sites for children are few and far between
View moreCCI-779: a new targeted anticancer agent
View moreChemoprevention: eat ginger, rub on pomegranate
View moreChemotherapy and anaesthetic drugs: too little is known
View moreChlorophyllin reduces risk of aflatoxin-induced liver cancer
View more
If you are a journal editor you can claim the journal profile and add new information for the visitors.
Comments